Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Central & Western Europe has been witnessing steady growth in recent years.
Customer preferences: The demand for Anti-Hypertensive Drugs has been increasing due to the rising prevalence of hypertension, which is a major risk factor for cardiovascular diseases. The aging population and sedentary lifestyles have also contributed to the growing demand for these drugs. Patients are increasingly preferring combination therapies that offer better efficacy and convenience in managing their condition.
Trends in the market: Germany is the largest market for Anti-Hypertensive Drugs in Central & Western Europe, followed by France and the United Kingdom. The market is dominated by branded drugs, but the trend is shifting towards generic drugs due to cost-effectiveness. The market is also witnessing the emergence of new drug classes such as renin inhibitors and aldosterone antagonists, which offer better efficacy and fewer side effects.
Local special circumstances: The healthcare systems in Central & Western Europe are highly regulated, and the reimbursement policies vary across countries. In some countries, the government provides universal healthcare coverage, while in others, private insurance companies cover a significant portion of healthcare costs. The pricing and reimbursement policies for drugs are determined by national authorities, and there is often a time lag between the approval of a drug and its availability in the market.
Underlying macroeconomic factors: The economic growth in Central & Western Europe has been moderate in recent years, and the region is facing challenges such as Brexit and trade tensions. The pharmaceutical industry is highly regulated and subject to price controls, which can impact the profitability of drug companies. The region also has a high level of healthcare expenditure, which is expected to increase due to the aging population and the rising burden of chronic diseases.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
